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Abstract 
Aims 
Depressive symptoms are commonly reported by haemodialysis (HD) patients. 
Previous reports have suggested an association between depression and nutritional 
status. To investigate this, we measured muscle mass in HD patients screened for 
depression. 
Methods 
The Beck Depression Inventory-II (BDI-II), Hospital Anxiety and Depression 
Scale (HADS) were used to screen for depression, and quality of life assessed by the 
short form 36 (SF36), and measured appendicular lean mass (ALM) post-dialysis with 
segmental bioimpedance.  
Results 
We studied 113 patients, 84 (74.3%) male, mean age 64.9 ±14.9 years, median 
duration of haemodialysis 27.0 (15.7-61.0) months, body mass index (BMI) post-dialysis 
25.2 (22.8-28.6) kg/m2, ALM index 6.98 (6.22-8.10) kg/m2. BDI-II 11 (4-17), HADS 10 
(5-16.5), and SF36 average 43.3(36.6-48.4). Lower ALM index was associated with 
greater BDI-II and HADS depression scores (r=0.29, p=0.008; r=0.27, p=0.012) 
respectively, and higher ALM index associated with improved scores on the SF36 
physical functioning and general health subscales (r=0.34, p=0.001; r=0.26, p=0.019), 
respectively. On logistic regression, lower ALM index was independently associated 
with high HADS cut off ≥8 (standardised β-0.31, p=0.007). There were no associations 
with weight, BMI or fat index. Greater extracellular water both pre- and post-dialysis 
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was associated with reduced SF36 physical functioning (r= -0.24, p=0.011, r=-0.22, 
p=0.26), respectively. 
Conclusion 
 This is the first report showing an association between ALM index and increased 
self-reported depression, anxiety and decreased general health. Whether treatment 
programs designed to improve muscle mass, can lead to reduced levels of depression, 
and anxiety and improved perceived general health, remains to be determined. 
 
 
Introduction 
 
Major depressive and mood affective disorders are reported to be more 
common in patients with chronic diseases. Although haemodialysis is an established 
treatment for chronic kidney disease, haemodialysis patients have an expected 5-year 
survival lower than that for some of the more common solid organ cancers [1]. Not only 
must haemodialysis patients cope with the disruption to life-styles imposed by 
attending for standard thrice weekly in-centre haemodialysis schedules, they are also 
required to comply with dietary and fluid restrictions, and a high pill burden. As such 
reports suggest that depression is common amongst dialysis patients, with prevalence 
rates varying between 39% based on self-reported screening and 23% based on 
psychiatric interview [2], with depressed haemodialysis patients having greater 
mortality [3]. However, depression is more difficult to diagnose because of the overlap 
of symptoms between depression and those associated with end stage kidney disease 
[4], with the screening self-reporting questionnaires containing several questions 
detailing assessments of fatigue [5,6]. Fatigue is a symptom commonly reported by 
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haemodialysis patients [5]. Patients with chronic kidney disease are more likely to 
suffer greater muscle loss, termed sarcopenia, due to a combination of multiple 
factors, including metabolic acidosis, vitamin D deficiency, insulin resistance, anaemia, 
reduced physical activity, testosterone deficiency in men, protein losses with dialysis, 
dietary restrictions and depression [7-10]. The European Society for Clinical Nutrition 
and metabolism (ESPEN) recommends bioelectrical impedance and dual electron 
absorptiometry (DEXA) scanning to assess muscle mass and body composition [11], and 
studies in haemodialysis patients have reported equivalence between methods [12]. 
Previous reports have demonstrated an association between loss of muscle mass, 
often termed sarcopenia, and depressive symptoms in the general population [13,14]. 
We therefore wished to determine whether there was an association between loss of 
muscle mass and self-reported depression and fatigue by comparing measurements of 
muscle mass with validated patient self-reported questionnaires. 
 
Methods 
 138 haemodialysis patients attending for outpatient haemodialysis treatments, 
dialysing under the care of a university hospital who met study entry criteria of being 
more than 18 years old, spoke English, and were able to provide written informed 
consent and  attending two RFH dialysis units, were screened for depression and 
anxiety using self-reporting questionnaires: Beck Depression Inventory-II (BDI-II) 
[6], Short-Form Health Survey (SF-36) [15], and the Hospital Anxiety and Depression 
Scale (HADS) [16].  Patient demographics and co-morbidity were recorded from 
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hospital computerised medical and dialysis records, and co-morbidity graded using the 
Stoke-Davies scale [17].  
113 patients had been established on haemodialysis for more 3 months and had 
corresponding bioimpedance measurements performed in a standardised manner both 
prior to and then after completion of the mid-week dialysis session using an eight 
electrode bioimpedance device (InBody 720, Seoul South Korea), as part of established 
routine clinical care [18,19]. Patients were allowed a recovery period after completion 
of the dialysis session prior to the post-dialysis bioimpedance measurement. 
Extracellular water (ECW) was expressed as a percentage of total body water (TBW), 
and ECW excess defined as difference between ECW measured and that predicted 
from intracellular water (ICW) as recommended by the ESPEN [11]. Sarcopenia was 
defined according to the European working group (EWGSOP) (7.25 kg/m2 for men and 
5.67 kg/m2 for women) [20]. Patients with amputations, and those with pacemakers and 
other implantable cardiac devices were excluded from study. 
Patients were dialysed using polysulphone dialyzers (Nipro, Osaka, Japan) [21], 
and Fresenius 4008H, 5008 (Fresenius AG, Bad Homberg, Germany) or BBraun 
Dialogue+ (BBraun, Melsungen, Germany) dialysis machines, using ultrapure dialysis 
water quality and anticoagulated with tinzaparin, a low molecular weight heparin (Leo 
Laboratories, Market Harborough, UK) [22].     
Serum biochemistry samples were analysed with a standard multi-channel 
biochemical analyzer (Roche Integra, Roche diagnostics, Lewes, UK), using the 
bromocresol green method for albumin determination, and haemoglobin samples by the 
sodium lauryl sulphate-Hb method (XE-2100 Sysmex Corporation, Kobe, Japan) [23]. 
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Ethics 
 All patients provided appropriate informed written consent in keeping with the 
Helsinki agreement, prior to receiving questionnaires. The study received ethical 
approval from Newcastle and North Tyneside 2 National Research Ethics Committee 
(ref 13-NE-0087). Patients who expressed suicidal ideation or whose score on any of 
the references tests gave cause for concern were discussed with a senior clinician in 
the research team and appropriate action taken. 
 
Statistical analysis 
 Data normality was checked using the D’Agostino-Pearson, and reported as mean 
and standard deviation, or median and interquartile range, or percentage and intergroup 
analysis was by standard methods with correction for repeated tests and for small 
numbers, where appropriate. After univariate analysis, multivariate logistic step 
backward analysis was used for determinants of an increased BDI score, and HADS, 
including variables significant on univariate analysis <0.1, and those thought to be 
clinically relevant; age, sex, C reactive protein, diabetic status, co-morbidity, ethnicity, 
months since starting HD, serum albumin, haemoglobin, ECW/TBW, and ALM index. 
Nonparametric parameters were log transformed. Variables were then excluded in a 
step backward analysis if not significant, or did not improve model fit, and models were 
checked for collinearity. Analyses were performed with Graph Pad Prism (Graph Pad 
Prism V6.0, San Diego, USA) and SPSS 24 (SPSS 24, University Chicago, Illinois, USA). 
Statistical significance was taken as p<0.05. 
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Results 
 We studied 113 patients, 84 (74.3%) male, mean age 64.9 ±14.9 years, median 
duration of haemodialysis 27.0 (15.7-61.0) months. Fifty-eight patients were of white 
ethnicity (51.3%), followed by 27 (23.9%) African Afro-Caribbeans and 27 (23.9%) 
Asians. Patient body composition, serum chemistries and self-reported questionnaires 
scores are set out in table 1. 
There were no statistical univariate associations between pre-dialysis weight or 
body mass index (BMI), haemoglobin, serum chemistries, months of haemodialysis 
treatment or β2 microglobulin, - a marker of residual renal function, dialysis sessional 
urea clearance, or Stoke-Davies co-morbidity score and BDI-II, HADS or SF36 self-
reported questionnaire scores. There were negative associations between the SF36 
physical functioning questionnaire and age (r=-0.22, p=0.02), both pre- and post-dialysis 
ECW/TBW (r= -0.24, p=0.011, r=-0.22, p=0.26), and ECW excess adjusted for total 
ECW again pre- and post-dialysis (r=-0.23, p=0.17, and r=-0.21, p=0.03), respectively. 
  We excluded patients with previous polio and severe limb disability following a 
stroke, and determined appendicular lean mass (ALM) index in 88 patients (table 2). 
There was no difference in the prevalence of sarcopenia between races (X2=4.8, 
p=0.19), or with diabetes, but more male patients had a reduced ALM index (X2=9.5, 
p=0.02). Reported HADS scores were greater for women. There were no differences 
for BDI-II or HADS between those with normal and reduced ALMI. There were 
differences with the SF36 scores for the male patients, for social functioning, general 
health and overall score (table 2). 
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 We then compared measurements of body composition with the self-reported 
questionnaire scores. To compare patients, measurements were indexed to height. 
Although there were no associations with fat mass index, there was a consistent 
association between estimations of muscle mass; fat free mass, soft lean mass and ALM 
and SF36 physical functioning (table 3). The greater the ALMI the higher the SF36 
scores, but there were negative associations between ALM index and depression scores 
with the BDI-II and HADS questionnaires. 
 Logistic regression models were analysed using a cut point score of ≥16 for the 
BDI-II [5], and ≥8 for the HADS questionnaire [24]. In the BDI-II model, patients 
with a high score were female and had been treated by haemodialysis for longer, and 
although loss of ALM (sarcopenia) remained in the model, ALM loss was not 
independently significant (p=0.06) (Table 4). Whereas in the HADS model, ALM index 
was independently associated with a lower HADS score, and increasing C reactive 
protein associated with a high HADS score. 
  
Discussion 
Studies of both peritoneal and haemodialysis patients have noted that dialysis 
patients report a higher level of depressive symptoms compared to age matched 
controls [2,4]. The standard screening questionnaires used to detect depression include 
questions related to fatigue. Despite the introduction of erythropoietins and the 
correction of anaemia, many dialysis patients also report fatigue [5].  
We did not find any association between the adequacy of dialysis treatments, or 
duration of haemodialysis treatments and self-reported depression screening and 
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health status questionnaire scores, in keeping with previous reports [25,26]. In keeping 
with previous reports, anxiety scores were greater for women than men, and more men 
generally reported more physical activity [25,27]. On the other hand, older age and 
increasing co-morbidity were not associated with greater self-reported depression or 
worse quality of life. Previous reports have proposed that patient perception of illness 
and wellbeing have a greater effect than chronological age or co-morbidity [28]. 
Patients gain fluid weight between haemodialysis sessions, and this excess fluid gain is 
then removed during the subsequent dialysis session. Whereas we found that increasing 
ECW, either pre- or post-dialysis was associated with a reduction in physical 
functioning, we did not find any association between increasing ECW, either pre- or 
post-dialysis and self-reported depression or anxiety scores. 
Previous studies have reported an association between depression and anxiety 
with nutrition in both the general population [13,14] and dialysis patients [29-31]. 
However, these earlier studies tended to use serum albumin, as a marker of nutritional 
status, and lower serum albumin concentrations may reflect inflammatory states, 
rather than malnutrition. More recently the interaction between inflammation and 
depression has been queried [32], suggestive of association rather than actual 
causality. Indeed, we found no univariate association with serum albumin, or cholesterol 
and the depression, anxiety or general health questionnaires.  
We report the first study in which body composition was measured by segmental 
bioimpedance. As bioimpedance measurements of muscle mass can be affected by 
overhydration [33], we made measurements after the mid-week haemodialysis session., 
to minimise this potential confounder. Patients were classified on the basis of reduced 
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ALM index, and whereas male patients were equally distributed, only a minority of 
women patients had a reduced ALM index. Although BDI-II scores were generally 
higher for those with reduced ALM index, the differences were not statistically 
different. On the other hand, HADS scores were similar for those with normal and 
reduced ALM index. General health and average health SF36 scores were greater for 
those men with a normal ALM index. On univariate analysis, we found no associations 
with fat mass index and depression, anxiety or general health scores, in keeping with a 
previous report which measured total body fat [34]. On the other hand, patients with 
reduced ALM index had higher BDI-II scores, and higher HADS scores, showing an 
association between reduced appendicular muscle and increased depression and anxiety. 
Whereas higher SF36 self-reported scores, suggestive of better general health were 
associated with greater appendicular muscle mass. Patients with greater muscle mass 
would be expected to be more physically active, with reports also observing a link 
between greater muscle mass and less co-morbidity [35,36]. 
We chose cut offs for the BDI-II and HADS scores based on previous reports 
[37,38].  Smaller single centre studies from other countries have suggested alternative 
cut off points [39]. Logistic regression models showed an association between high 
self-reported BDI-II scores suggestive of depression and female gender and duration 
of haemodialysis treatment. Longer duration of haemodialysis is generally associated 
with loss of residual renal function, which has been previously reported to be a factor 
associated with increased depression [40]. Although reduced ALM (sarcopenia) was 
retained within the model, it was not independently associated with a high BDI-II 
score.  ALM index was independently associated with a high anxiety distress score, 
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with lower ALM index associated with greater anxiety and distress, as was C reactive 
protein. However, the strength of these models was weak with an r2 value of <0.15, and 
as such these associations should not be over interpreted. However, our results would 
be supported by reports of isometric exercise in patients with chronic kidney disease 
improving [41]. 
We report an association between reduced appendicular muscle mass measured 
by segmental bioimpedance and increased self-reported depression, anxiety and lower 
general health. Our study can only report an association, and whether treatment 
programs designed to improve muscle mass, lead to reduced levels of depression, and 
anxiety and improved perceived general health, or whether effective treatments for 
depression and anxiety might conversely improve muscles mass remains to be 
determined. 
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Table 1. Patient cohort demographics. Body composition results post dialysis. 
Serum haemoglobin and chemistries pre-dialysis. Results expressed as integer, 
percentage, mean ±standard deviation or median and interquartile range. 
 
variable  
Weight pre-dialysis kg 73.7 ±18.9 
Weight post-dialysis kg 72.1 ±18.9 
Body mass index kg/m2 25.2 (22.8-28.6). 
Extracellular water/total body water pre-dialysis 39.8 ±1.4 
Extracellular water/total body water post-dialysis 39.0 ±1.6 
Fat mass kg 22.2 (15.3-28.4) 
% body fat 31.4 (22.2-38.2) 
Fat free mass kg 47.4 (42.3-56.5) 
Fat free mass index kg/m2 17.8 (15.9-19.2) 
Appendicular lean mass kg 19.1 (16.2-24.3) 
Appendicular lean mass index kg/m2 6.98 (6.22-8.10) 
Haemoglobin g/L 114.0 ±14.5 
Urea mmol/L 18.4 ±4.6 
Creatinine umol/L 714 (584-886) 
Albumin g/L 40.3 ±3.4 
Cholesterol mmol/L 4.1 ±1.0 
C reactive protein mg/L 5 (2-12) 
Calcium mmol/L 2.39 ±0.15 
Phosphate mmol/L 1.47 ±0.39 
Glucose mmol/L 6.2 (5.2-7.6) 
Β2 microglobulin mg/L 25.6 (20-32.5) 
Dialysis urea reduction ratio 74.5 ±7.5 
On-line sessional dialysis clearance 1.43 ±0.22 
Past history myocardial infarction % 11.5 
Coronary artery bypass surgery % 13.3 
Coronary artery stenting % 8.0 
Peripheral vascular disease % 3.5 
Transient ischaemic attack % 7.1 
Cerebrovascular disease % 17.7 
Diabetes mellitus % 39.8 
Stoke-Davies co-morbidity score 1 (0-2) 
Hospital Anxiety Depression Score total 10 (5-16.5) 
Beck Depression Inventory -II 11 (4-17) 
Short Form 36 physical functioning 45 (15-65) 
Short Form 36 physical role 0 (0-50) 
Short Form 36 energy 50 (30-60) 
Short Form 36 general health 35(30-40) 
Short Form 36 average 43.3(36.6-48.4) 
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Table 2. Patients were divided into those with normal or reduced appendicular 
lean mass index (ALMI). Beck Depression Inventory -II (BDI-II), Hospital 
Anxiety Depression Score (HADS), Short Form 36 (SF36).  Results expressed 
as integer, or median and interquartile range. * p<0.05 vs normal ALMI. 
 
 
 Normal ALMI Reduced 
ALMI 
Normal ALMI Reduced 
ALMI 
variable female female male male 
number 15 5 34 34 
HADS anxiety 7(3-8) 7.5(5.5-8.0) 3(1-7) 4(0-7) 
HADS 
depression 
8(6-9) 8.5(4.5-10) 4(1-6) 4(2-8) 
HADS total 14(8-20) 15(10-18) 7(4-12) 9(3-15) 
BDI-II 13(9-17) 20(10-20) 6(2-12) 10(6-15) 
SF36 physical 
functioning 
45(15-55) 20(25-50) 57.5(30-85) 45(20-65) 
SF36 physical 
role 
0(0-0) 12.5(0-37.5) 25(0-75) 0(0-25) 
SF36 emotional 66.7(0-100) 83.3(33.3-
100) 
100(100-100) 100(33.3-
100) 
SF36 energy 50(35-55) 32.5(25-45) 50(45-60) 55(35-65) 
SF36 emotional 
wellbeing 
72(60-84) 76(64-84) 84(64-92) 78(68-88) 
SF36 social 
functioning 
50(37.5-50) 87.5(56.3-
100) 
93.8(50-100) 62.5(37.5-
75)* 
SF 36 pain 65(45-90) 41.3(17.5-
78.8) 
88.8(70-100) 90(45-
100) 
SF36 general 
health 
35(30-40) 27.5(22.5-
57.5) 
55(35-80) 40(25-
60)* 
SF36 average 43.3(36.6-
48.4) 
47.5(32.1-
64.6) 
68.8(51.9-
78.8) 
52.4(42.8-
72.3)* 
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Table 3.  
Univariate Spearman association between body composition and self-reported 
questionnaires. Beck Depression Inventory -II (BDI-II), Hospital Anxiety Depression 
Score (HADS), Short Form 36 (SF36).   
variable questionnaire r p 
Fat free mass index SF36 physical functioning 0.32 <0.001 
 SF36 social functioning 0.26 0.013 
Soft lean mass index SF36 physical functioning 0.31 0.006 
 SF36 physical role 0.22 0.042 
Appendicular lean mass index BDI-II -0.29 0.008 
 HADS depression -0.27 0.012 
 HADS total -0.22 0.041 
 SF36 physical functioning 0.34 0.001 
 SF36 physical role 0.26 0.016 
 SF36 energy 0.22 0.043 
 SF36 general health 0.26 0.019 
 
 
 
 
 
Table 4. Logistic regression models using a BDI-II cut point ≥16 and HADS cut point ≥8. 
Unstandardised beta coefficient (β coeff), standard error (StE), standardised beta 
coefficient (St β), 95% limits of agreement (95 LA). Duration of haemodialysis 
treatment (Vintage), Appendicular lean mass (ALM), reduced ALM index meets criteria 
for sarcopenia. Models, r2 0.181, adjusted r2 0.148; and r2 0.154, adjusted r2 0.121, 
respectively.  
 Β coeff StE β St β t 95% LA p 
BDI model       
Female gender 0.35 0.12 0.32 2.9 0.9 to 1.0 0.004 
Log Vintage months 0.16 0.06 0.28 2.6 1.0 to 1.1 0.010 
Reduced ALM index 0.18 0.09 0.26 1.9 0.9 to 1.1 0.060 
HADS model       
ALM index kg/m2 -0.11 0.04 -0.31 -2.8 -1.9 to -0.3 0.007 
Log CRP mg/L 0.21 0.07 0.25 2.3 0.03 to 0.39 0.023 
Urea mmol/L 0.02 0.01 0.19 1.8 -0.01 to 0.05 0.080 
 
